AAV Serotype-1 mediates early onset of gene expression in mouse hearts and results in better therapeutic effect
Authors:
Open Access
- 15 June 2006
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 13 (21) , 1495-1502
Abstract
Adeno-associated viral vectors (AAV) are attractive tool for gene therapy for coronary artery disease. However, gene expression in myocardium mediated by AAV serotype 2 (AAV2) does not peak until 4–6 weeks after gene transfer. This delayed gene expression may reduce its therapeutic potential for acute cardiac infarction. To determine whether earlier gene expression and better therapeutic effect could be achieved using a different serotype, CMV promoter driving the EPO gene (AAV-EPO) was packaged into AAV serotypes 1–5 capsids and injected into mouse myocardium. EPO expression was studied by measuring the hematocrits and EPO mRNA. After we found that AAV1 mediates the highest gene expression after 4 days of gene transduction, AAV-LacZ (CMV promoter driving LacZ gene expression) and MLCVEGF (hypoxia-inducible and cardiac-specific VEGF expression) were packaged into AAV1 and 2 capsids. LacZ expression was detected in AAV1-LacZ but not in AAV2-LacZ-injected hearts 1 day after vector injection. Compared to AAV2-MLCVEGF that mediated no significant VEGF expression, AAV1-MLCVEGF mediated 13.7-fold induction of VEGF expression in ischemic hearts 4 days after gene transduction and resulted in more neovasculatures, better cardiac function and less myocardial fibrosis. Thus, AAV1 mediates earlier and higher transgene expression in myocardium and better therapeutic effects.Keywords
This publication has 46 references indexed in Scilit:
- Adeno-associated viral vector delivers cardiac-specific and hypoxia-inducible VEGF expression in ischemic mouse heartsProceedings of the National Academy of Sciences, 2004
- Pre-emptive gene therapy using recombinant adeno-associated virus delivery of extracellular superoxide dismutase protects heart against ischemic reperfusion injury, improves ventricular function and prolongs survivalGene Therapy, 2004
- Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapyProceedings of the National Academy of Sciences, 2002
- Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart modelProceedings of the National Academy of Sciences, 2002
- Several Log Increase in Therapeutic Transgene Delivery by Distinct Adeno-Associated Viral Serotype VectorsMolecular Therapy, 2000
- Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heartProceedings of the National Academy of Sciences, 2000
- Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous systemProceedings of the National Academy of Sciences, 2000
- Long-Term Gene Transfer in Porcine Myocardium After Coronary Infusion of an Adeno-Associated Virus VectorThe Annals of Thoracic Surgery, 1996
- Nucleotide Sequencing and Generation of an Infectious Clone of Adeno-Associated Virus 3Virology, 1996
- The cryptic life style of adenoassociated virusBioEssays, 1995